

Contents

Prologue — VI

1 Basic concepts in pharmaceutical chemistry — 1

- 1.1 Goals — 1
- 1.2 Basic concepts and purposes of pharmaceutical chemistry — 1
- 1.3 Historical development of pharmaceutical chemistry — 3
 - 1.3.1 The pre-scientific period (~ 3000 years BC until the 19th century) — 3
 - 1.3.2 Scientific period (19th century to 1960) — 4
 - 1.3.3 Current period (from the 1960s to the present) — 4
- 1.4 Patents — 5
- 1.5 Multidisciplinary nature of this discipline — 6
- 1.6 Origin of drugs — 7
- 1.7 Other definitions — 7
- 1.8 Classification of drugs — 8
- 1.9 Process of discovery of a drug — 8
- 1.10 Phases of clinical studies — 9

2 Drug nomenclature — 10

- 2.1 Goals — 10
- 2.2 Nomenclature of drugs — 10
- 2.3 Systematic chemical names — 11
- 2.4 Polyfunctional acyclic compounds — 12
- 2.5 Monocyclic compounds — 13
- 2.6 Polycyclic aromatic hydrocarbons (PAHs) — 15
- 2.7 Partly or fully hydrogenated polycyclic hydrocarbons — 17
- 2.8 Bicyclic hydrocarbons — 18
 - 2.8.1 Bridge systems — 18
 - 2.8.2 Bicyclic systems with heteroatoms — 19
 - 2.8.3 Spiro or spirane systems — 20
- 2.9 Heterocycles — 22
 - 2.9.1 Condensed heterocycles — 26
- 2.10 Numbering of condensed heterocycles — 27
- 2.11 Criteria for choosing the base heterocycle — 27
- 2.12 Heterocycles condensed with benzene — 30
- 2.13 Exercises — 31

3 Search for prototypes — 37

- 3.1 Goals — 37
- 3.2 Traditional and current discovery of new drugs — 37
 - 3.2.1 Screening of natural products — 38

3.2.2	Existing drugs used as leaders —	40
3.2.3	Isolation and identification of drug metabolites —	42
3.2.4	Examples of serendipity —	42
3.3	Planned syntheses of new chemical compounds on rational bases —	44
3.4	Isolation and purification —	44
3.5	Structural determination —	45
4	Optimisation of prototypes —	46
4.1	Goals —	46
4.2	Molecular manipulation —	46
4.2.1	Purpose —	46
4.2.2	Strategies —	50
4.3	Modulative structural variation —	51
4.3.1	Vinylogy —	51
4.3.2	Homology —	53
4.3.3	Introduction of cyclic systems —	53
4.3.4	Introduction or substitution of polar groups, by nonpolar bulky ones —	53
4.3.5	Isosterism and bioisosterism —	54
4.4	Disjunctive replication —	59
4.5	Conjunctive replication —	61
4.6	Peptidomimetics —	61
4.7	Exercises —	63
5	Biological targets and receptors for drugs —	70
5.1	Goals —	70
5.2	Membrane receptor —	70
5.3	Affinity and intrinsic activity; agonists and antagonists —	71
5.4	Types of receptors —	71
5.4.1	Ionic channels —	71
5.4.2	Receptors with an intrinsic catalytic activity —	72
5.4.3	Receptors bound to G proteins —	73
5.4.4	Intracellular receptors —	74
5.5	Types of bonds: energy range (kJ/mol) per interaction —	75
5.5.1	Intramolecular bonding interactions —	75
5.5.2	Intermolecular interactions —	75
5.5.3	Hydrophobic bond —	77
5.6	Conformation and activity: use of rigid analogues —	78
5.7	Absolute configuration and activity: difference between enantiomers —	82
5.8	Relative configuration and activity —	83
5.9	Exercises —	85

6	Quantitative drug design: parameters and quantitative structure activity relationships — 90
6.1	Goals — 90
6.2	Introduction — 90
6.2.1	Electronic parameters — 91
6.2.2	Hydrophobic parameters: partition coefficient and hydrophobic substituent constant — 93
6.2.3	Steric parameters — 95
6.3	Craig plot — 97
6.4	Hansch equation — 98
6.5	3D QSAR model — 98
6.6	CoMFA advantages over traditional QSAR — 100
6.7	Potential problems of CoMFA — 100
6.8	Exercises — 101
7	Metabolic processes in drugs: other methodologies available for the discovery of new drugs — 107
7.1	Goals — 107
7.2	Metabolism studies and their use in the discovery of new drugs — 107
7.3	Absorption — 107
7.4	Lipinski's rules — 109
7.5	Metabolism — 110
7.5.1	Phase I reactions — 110
7.5.2	Phase II reactions — 115
7.6	Prodrug concept — 119
7.6.1	Improvements in the galenic characteristics — 119
7.6.2	Pharmacokinetic improvements — 120
7.7	Modulation of drug metabolism — 122
7.8	Suppression of the metabolic processes — 122
7.9	Promotion of nonoxidative metabolism — 123
7.10	Exercises — 125
8	Synthetic drug strategies — 128
8.1	Goals — 128
8.2	Introduction to disconnections — 128
8.3	Definitions — 129
8.4	Rules to make a good disconnection — 130
8.5	<i>endo</i> selectivity — 132
8.6	Synthesis of various barbiturates — 133
8.6.1	Pentobarbital — 133
8.6.2	Phenobarbital — 133
8.6.3	Hexobarbital — 135
8.7	Buprenorphine — 135

8.8	Rofecoxib —	138
8.9	Fentanyl —	139
8.10	Gefitinib —	140
8.11	Exercises —	142
9	Solutions to the exercises —	143
9.1	Exercises to chapter 2 —	143
9.2	Exercises to chapter 4 —	146
9.3	Exercises to chapter 5 —	148
9.4	Exercises to chapter 6 —	155
9.5	Exercises to chapter 7 —	159
9.6	Exercises to chapter 8 —	167
Index —		173